April 18, 2017 5:53pm

 

Which has raised serious questions about what “our” universe is accomplishing?

 

The sector moves on the lack of news and expectation thus doesn’t perform in a sustainable manner in any session  

Its approach to share pricing is lagging which has kept the “machines” selling off

 

Pre-open indications:  3 hit and 2 miss

 

I answer one question, in which company should investors commit and keep their money

 

The truth is harsh, but reality is what it is; get the sector’s daily interpretation in your email …

 

 

RMi’s daily and continual “reads” of the goings-on of the SCG&RT sector can improve investor’s and trader’s odds - just because a stock underperforms the market doesn’t mean you have to lose money.

 

 

Henry’omics:

From the pre-open’s investor’s letter title, “What’s up, next and on tap for Tuesday? Think about how companies are defined lately – by ETF exposure! That exposure keeps telling us they are an “arbitrage mechanism” to lower volatility – is it time for some serious sarcasm?”

  • Investors see losses and temporary gains in trading came as traders, ETFs and algorithms readjusted their portfolios ahead of the uncertainty of Q1/17 financial results being announced.

To be sure, there could be some rebound as volatility revs up and down but cash positions will be highlighted as well as some company’s ability to jump through the capital market window without the severe depreciation and dilution experienced by those who raised money in Q1/17.

  • Reiterating, “Q2 is going to be more of the same but, I see a calamity in regard to cash positions for some as equities will stick to the current seesaw of performance for most of the cell therapy sector.”

 

What’s to keep investors staying or attracted to “our” universe?

·         It sure isn’t share pricing!

 

 

What analytics were there today and why it was important in today’s sector outcomes?

… The DOW closed down -113.64 or -0.55% to 20,523.28 while the NASDAQ closed down -7.32 or -0.12% to 5849.47 …

… The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded near 14.4 …

·         Monday traded near 15 …-7% lower following Thursday’s 16 after Wednesday’s 15.75 post last Tuesday’s 15.14, +7% higher;

·         The iShares Russell 2000 (IWM) indicated a positive +0.12% at the pre-open was and closed UP +0.02%;

… The iShares NASDAQ Biotechnology (IBB) did NOT indicate at the pre-open and closed DOWN -1%.

 

The advance/decline line scenario of 43 SCGT & RT covered companies:   

·         The open was negative with an A/DL of 9/33 and 1 flat;

·         The mid-day stayed negative with an A/DL of 10/33 and 0 flat;

·         The close was negative with an A/DL of 10/31 and 2 flats;

 

… Decliners ranged from -0.33% <KOOL> to -14.47% <NWBO> in 31 equities;

… Gainers ranged from +0.24% <RGNX> to +3.03% <ISCO> in 10 equities;

 

Pre-open indications:  3 hit and 2 miss:

  • Applied Genetic Technologies (AGTC) up +$0.10 – hit;
  • AxoGen (AXGN) closed down -$0.30 – hit;
  • Kite Pharma (KITE) closed down -$2.47 – miss;
  • Regenxbio (RGNX) closed up +$0.05 – miss;
  • Verastem (VSTM) closed down -$0.16 – hit;

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.